1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Endo Continues To Expand Generics Business With Par Acquisition

After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.

While it may have lost out on building out its brand business with gastrointestinal-focused Salix Pharmaceuticals Ltd., Endo International PLC is betting that its $8 billion buy-out of Par Pharmaceutical will not only expand its generic business but increase the growth rate in that unit with a focus on alternative dosage formulations and products that will be difficult for competitors to replicate.

Endo announced May 18 that it will acquire Par [See Deal], taken private by TPG Capital in 2012,...

More from United States

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 
• By Michael McCaughan

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By Cathy Kelly

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

More from North America

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.